Applications of 1-(5-Isoquinolinylsulfonyl)-3-Methyl-Piperazine Dihydrochloride in Industrial Manufacturing

As the direct manufacturer of 1-(5-Isoquinolinylsulfonyl)-3-Methyl-Piperazine Dihydrochloride, we supply this specialty intermediate for tightly regulated and technically demanding sectors. Below we detail practical industrial applications, compliance requirements, formulation protocols, downstream process nodes, and the types of finished products enabled by this compound.

1. Tyrosine Kinase Inhibitor Development in Pharmaceutical Synthesis

This chemical serves as a key sulfonylation and piperazinylation reagent during the preparation of certain small-molecule tyrosine kinase inhibitors. It delivers specific inhibitory activity profiles in preclinical and clinical candidates targeting oncology indications. Formulation teams introduce it at defined stoichiometric steps to modify core scaffolds or improve water solubility. Process chemists must maintain strict traceability and impurity thresholds for submission to regulatory authorities.

Industry compliance standards

• ICH Q7, Q11 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• 21 CFR Part 211 (US FDA CGMP for Finished Pharmaceuticals)
• European Pharmacopoeia monographs (when applicable to finished APIs)
• ICH M7 (Assessment and Control of DNA Reactive Impurities)

Typical usage ratio

• 0.8 to 1.3 molar equivalents, adjusted depending on the target substrate’s reactivity and step yield optimization determined during development

Downstream process integration

• Reagent added at the late-stage sulfonamide formation during fragment coupling
• Purified post-reaction by preparative chromatography prior to API crystallization

Final product types

• Active pharmaceutical ingredient (API) intermediates for clinical kinase inhibitor pipelines
• Final formulated oral or injectable oncology drugs

2. Enzyme Inhibitor Reagents for Biochemical R&D and Assay Kits

Researchers employ this molecule as a biochemically selective inhibitor in enzyme screening, cell signaling, and kinase assay development. It becomes a critical component in validated biochemical kits used by academic and pharmaceutical discovery labs. Preparation must achieve high purity for compatibility with downstream biological assays. All lots require traceable QC records supporting research use declarations.

Industry compliance standards

• ISO 9001:2015 (Quality management for laboratory chemical batch production)
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals, EU lab chemical use)
• OECD Principles of Good Laboratory Practice (GLP, for reference standards in regulated assays)
• USP General Chapter <1010> Analytical Reference Standards (as applicable for kit components)

Typical usage ratio

• 2–20 μM in in vitro enzyme assays; concentration tailored by the inhibitory constant (Ki) and application-specific validation against the target kinase

Downstream process integration

• Dissolved in DMSO or buffer during assay kit reagent preparation
• Aliquoted into individual test vials after QC verification of concentration and activity

Final product types

• Biochemical inhibitor assay kits for target validation
• Enzyme profiling services involving kinase/substrate screening

3. Chemical Synthesis Intermediate for Contract Manufacturing Organizations (CMOs)

Contract manufacturing organizations utilize this compound as a functionalizing intermediate during custom synthesis of complex heterocyclic molecules for preclinical studies. Integration requires validated supply-chain traceability, batch-level impurity data, and alignment with international CMO/contractual QC protocols. Its use extends only to well-documented, regulated synthetic schemes in defined customer R&D workflows.

Industry compliance standards

• ISO 13485:2016 (Quality management for medical device and diagnostic reagent manufacturing)
• ICH Q11 (Development and Manufacture of Drug Substances)
• Chemical Facility Anti-Terrorism Standards (when shipped internationally, US DHS)
• GMP guidelines for custom synthesis projects

Typical usage ratio

• 0.2–1.5 equivalents, determined by target molecule complexity, step yield history, and downstream purification constraints

Downstream process integration

• Charged to the reaction after initial cyclization or heterocyclic core assembly
• Recovered or neutralized by controlled extraction and chromatographic purification upstream of the final product isolation

Final product types

• Advanced intermediates for proprietary drug discovery
• Pilot lots of screening compounds for structure-activity relationship (SAR) studies

4. Signal Transduction Pathway Inhibitors in Molecular Biology Reagent Production

This compound features in specialized reagent kits supporting cell biology and molecular signaling pathway research. Production requires trace lot-level validation for signal pathway specificity and absence of off-target activity. Manufacturing teams package the reagent into individual research-grade vials for controlled freeze-thaw cycles and stability-managed global logistics. Regulatory statements and MSDS documentation must accompany each shipment to institutional buyers.

Industry compliance standards

• ISO 13485:2016 (Medical and diagnostics reagent kit production)
• REACH Annex II (Safety Data Sheet requirements for chemicals used in labs, EU)
• OSHA Hazard Communication Standard (29 CFR 1910.1200, US)
• Good Laboratory Practice (GLP) compliance for regulated research applications

Typical usage ratio

• 10–50 μM per cell culture assay, titrated based on experimental design, cell type, and inhibition curve

Downstream process integration

• Packaged as lyophilized reagent or frozen solution for direct addition to cell culture media
• Supplied with analytical certificate verifying lot-specific activity

Final product types

• Signal transduction inhibitor reagent kits
• Research-use-only (RUO) molecular biology product lines

5. Preclinical Drug Screening Compounds in CRO Services

Contract research organizations (CROs) leverage this compound as a standardizable probe in kinase signaling pathway panels and toxicity models. Purity and batch consistency directly affect reproducibility of screening data. Production teams coordinate with CRO end-users to deliver customized packaging, transport under temperature control, and stability testing batches as per client study protocols. All documentation clarifies intended RUO (research use only) status, not for use in humans.

Industry compliance standards

• ISO 9001:2015 (Custom chemical supply for research applications)
• REACH (Annex XVII restrictions for research-use chemicals)
• GLP (OECD requirements for nonclinical safety studies)
• US EPA TSCA inventory compliance for nonclinical compounds

Typical usage ratio

• 5–30 μM per in vitro screening well, fine-tuned by specific kinase and toxicity model parameters

Downstream process integration

• Diluted into appropriate assay solvents at the CRO facility following delivery in sealed, pre-calibrated containers
• Validation checks performed by the CRO QC on arrival and prior to study

Final product types

• Standardized research probe compound sets
• Kit-based panels for large-scale kinase inhibitor screening assays